Powered by

Genprex Provides Clinical and Corporate Update for Third Quarter 2018

Nov 20, 2018 - Business Wire
Board and Executive Moves

Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced a clinical and corporate update, and the filing of quarterly results for the third quarter ended September 30, 2018 on Form 10-Q with the Securities and Exchange Commission.

Rodney Varner, Chairman and CEO, remarked, "Over the past quarter, we have taken steps to advance our clinical development activities. We ex...